EUVIMEDEUVIMED entdecken
Crossref

Novel Index Based on Inflammatory Markers Correlates with Treatment Efficacy of Nivolumab for Recurrent/Metastatic Head and Neck Cancer

Hiroe Tada, Reika Kawabata-Iwakawa, Hideyuki Takahashi, Kazuaki Chikamatsu

Oncology · 2024

DOI: 10.1159/000542683 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Hiroe Tada und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan. Hauptthemen laut MEDLINE: Nivolumab, Head and Neck Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune checkpoint inhibitors provide new treatments for patients with recurrent or metastatic (R/M) head and neck cancers. Herein, we focused on systemic inflammatory markers in peripheral blood, including blood cell fractions, albumin (Alb), and C-reactive protein, and determined their association with nivolumab treatment response. We also examined the potential application of inflammatory markers as prognostic tools.

Methods

We assessed pretreatment systemic inflammatory markers in 61 patients with R/M head and neck cancer treated with nivolumab, determining their association with treatment response using Kaplan-Meier, multivariate, and regression analyses. Using flow cytometry, we investigated circulating T-cell subsets in 36 patients with R/M head and neck cancer. Finally, we examined the correlation between each statistically analyzed parameter and peripheral circulating T-cell activation.

Results

Systemic inflammatory marker values were used to estimate overall survival (OS) time by performing multivariate analysis. Systemic inflammatory markers were assigned importance for each coefficient. Monocyte and lymphocyte counts strongly impacted OS. Indices dependent on white blood cell and monocyte counts, lymphocyte percentage, platelet count, Alb levels, and prognostic nutrition index were useful prognostic tools in the regression analysis. The simplest prognostic index was defined as white blood cells (103/μL) +2 × lymphocyte percentage (%) +12 × number of monocytes (103/μL) + 27 × serum Alb. A high index that was significantly associated with a better prognosis negatively correlated with CD38/CD8 and ki67/CD8 percentages.

Conclusions

According to the findings of the present study, systemic inflammatory markers may help predict the prognosis, activation, and exhaustion of circulating T cells. In patients with R/M head and neck cancer treated with nivolumab, systemic inflammatory markers could provide new insights into rational strategies in cancer immunotherapy for R/M head and neck cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabHead and Neck NeoplasmsImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalNeoplasm MetastasisBiomarkers, TumorInflammationHumansT-Lymphocyte SubsetsSurvival AnalysisLymphocyte CountRetrospective StudiesMaleFemaleAdultMiddle AgedAgedAged, 80 and over

Stichwörter der Autor:innen

CD8+ T cellCirculating T cellNivolumabRecurrent/metastatic head and neck cancerSystemic inflammatory markers

Substanzen

NivolumabImmune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan.
  • Division of Integrated Oncology Research, Gunma University, Initiative for Advanced Research, Maebashi, Japan.

Zitieren

APA

Tada, H., Kawabata-Iwakawa, R., Takahashi, H., & Chikamatsu, K. (2024). Novel Index Based on Inflammatory Markers Correlates with Treatment Efficacy of Nivolumab for Recurrent/Metastatic Head and Neck Cancer. Oncology. https://doi.org/10.1159/000542683

Vancouver

Tada H, Kawabata-Iwakawa R, Takahashi H, Chikamatsu K. Novel Index Based on Inflammatory Markers Correlates with Treatment Efficacy of Nivolumab for Recurrent/Metastatic Head and Neck Cancer. Oncology. 2024. doi:10.1159/000542683

BibTeX
@article{Tada2024,
  author = {Tada, Hiroe and Kawabata-Iwakawa, Reika and Takahashi, Hideyuki and Chikamatsu, Kazuaki},
  title = {Novel Index Based on Inflammatory Markers Correlates with Treatment Efficacy of Nivolumab for Recurrent/Metastatic Head and Neck Cancer},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000542683}
}
Kostenlos starten →